Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Inclusion Criteria:

* Histologically or cytologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer

  * Recurrent or metastatic disease
* Measurable disease, defined as ≥ 1 unidimensionally measurable indicator lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
* Must have received a platinum-containing chemotherapy regimen for primary disease

  * Re-treatment with a platinum-based regimen required for patients who achieved a clinical complete response (CR) to primary therapy and then had a treatment-free interval \> 12 months (i.e., platinum-sensitive) unless the patient developed a hypersensitivity to platinum

    * Patients with a treatment-free interval \< 12 months do not require prior chemotherapy for recurrent disease
* No evidence of CNS disease, including primary brain tumors or brain metastasis
* Performance status - ECOG 0-2
* More than 3 months
* WBC ≥ 3,000/mm\^3
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* No history of bleeding diathesis
* SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if due to liver metastasis)
* Bilirubin normal
* INR ≤ 1.5 (3 if receiving warfarin)
* No history of esophageal varices
* Creatinine ≤ 1.5 mg/dL
* Creatinine clearance ≥ 60 mL/min
* Urine protein \< 1+
* Urine protein \< 1,000 mg on 24-hour urine collection
* Urine protein:creatinine ratio \< 1.0
* No arterial thromboembolic event within the past 6 months, including any of the following:

  * Transient ischemic attack
  * Cerebrovascular accident
  * Unstable angina pectoris
  * Myocardial infarction
* No clinically significant peripheral artery disease
* No uncontrolled hypertension
* No New York Heart Association grade II-IV congestive heart failure
* No serious cardiac arrhythmia requiring medication
* No peripheral vascular disease ≥ grade 2
* Not pregnant
* No nursing during and for ≥ 3 months after study participation
* Negative pregnancy test
* Fertile patients must use effective contraception during and for ≥ 3 months after study participation
* No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs (e.g., Chinese hamster ovary cell products or recombinant humanized antibodies)
* No serious or non-healing wound, ulcer, or bone fracture
* No active infection requiring parenteral antibiotics
* No other active malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
* No gastrointestinal tract disease resulting in an inability to take oral medication
* No significant traumatic injury within the past 28 days
* No known HIV positivity
* No prior bevacizumab
* See Disease Characteristics
* No more than 2 prior cytotoxic chemotherapy regimens for recurrent or refractory disease (i.e., failed to achieve a clinical CR after primary therapy)
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
* More than 4 weeks since prior radiotherapy
* No prior radiotherapy to any indicator lesion unless disease has progressed since completion of radiotherapy
* More than 4 weeks since prior major surgical procedure or open biopsy
* More than 1 week since prior core biopsy
* No prior surgery affecting absorption
* No concurrent major surgery
* Recovered from prior therapy
* No prior vascular endothelial growth factor (VEGF) or an epidermal growth factor receptor (EGFR) directed therapy
* No prior erlotinib
* At least 30 days since prior investigational drugs
* More than 1 month since prior thrombolytic agents
* Concurrent warfarin allowed provided the following criteria are met:

  * Patient is on a therapeutic stable dose of warfarin
  * INR ≤ 3
  * No active bleeding or pathological condition that would confer a high risk of bleeding (e.g., tumor invading adjacent organs or major blood vessels or varices that are likely to bleed)
* No other concurrent investigational agents
* No other concurrent anticancer therapy